Liminatus Pharma, Inc. (LIMN) intrinsic value & 10-year financials
Liminatus Pharma, Inc. (LIMN) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.04
- Market cap
- $72.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -182.0%
- Free cash flow (FY2025)
- -$10.0M
LIMN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$10.2M | -$0.43 | -$10.0M | — | 251.0% |
| FY2024 | — | -$3.5M | -$0.20 | — | — | -615.0% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Liminatus Pharma, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Liminatus Pharma, Inc. has historically struggled to out-earn its cost of capital, averaging just -1.8% ROIC.
Liminatus Pharma, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Liminatus Pharma, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.